Trial Profile
A phase I trial of TNF [tumour necrosis factor]-bound colloidal gold (CYT-6091) by intravenous administration in subjects with advanced solid organ malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs CYT 6091 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.